RxDoctor Payments Data

Brundha Balaraman, MD

Dermatology · Sugar Land, TXNPI 1437461258

Payments from drug & device makers

$14,006in general payments, 2019–2025

Across 506 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aclaris Therapeutics, Inc.$5K
  • Johnson & Johnson$1K
  • AbbVie$1K
  • Novartis$965
  • Galderma Laboratories, L.p.$710
  • Amgen$576
  • plus $4K from 28 others

What the payments were for

  • Speaking & faculty fees$4,50032%
  • Food & beverage$9,31166%
  • Education$1951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,006 in reported general payments places this provider in the 75th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$205,262
Medicare patients
389
Services billed
2,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$53,735
JubliaEfinaconazole12$8,552
Clobetasol Propionate146$5,680
Ketoconazole201$2,785
Fluocinonide53$2,015
Triamcinolone Acetonide145$1,926
Clindamycin Phosphate52$1,603
Fluorouracil20$1,392
Metronidazole23$1,365
Ciclopirox56$1,201
Tretinoin19$974
Doxycycline Hyclate51$905
Hydrocortisone128$867
Minoxidil65$627
CiclopiroxCiclopirox Olamine24$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$576$53,73511 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$114$8,55212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →